Vyondys 53 Clinical Development Timeline

Chronicle of the development and review of Sarepta’s golodirsen for treatment of Duchenne muscular dystrophy patients with a genetic mutation amenable to exon 53 skipping.

More from Drug Review Profiles

More from Product Reviews